Lestaurtinib Completed Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00079482Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)